<DOC>
	<DOCNO>NCT00039273</DOCNO>
	<brief_summary>RATIONALE : Monoclonal antibody locate tumor cell either kill deliver tumor-killing substance without harm normal cell . PURPOSE : Phase II trial study effectiveness monoclonal antibody therapy treat patient relapsed refractory metastatic colorectal cancer .</brief_summary>
	<brief_title>Monoclonal Antibody Therapy Treating Patients With Metastatic Colorectal Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Determine response rate patient metastatic colorectal cancer treat monoclonal antibody ABX-EGF . - Determine additional measure clinical efficacy drug , term progression-free survival , overall survival , time treatment failure , patient . - Determine safety drug patient . OUTLINE : This multicenter study . Patients receive monoclonal antibody ABX-EGF IV 1 hour weekly week 1-8 . Treatment repeat every 8 week 6 course absence disease progression unacceptable toxicity . Patients follow 4 week , every 3 month 1 year , every 6 month 1 year . PROJECTED ACCRUAL : A total 20-100 patient accrue study .</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically confirm colorectal carcinoma Diagnosed fineneedle aspirate tissue biopsy Metastatic disease No squamous cell carcinoma Relapsed refractory prior chemotherapy irinotecan fluoropyrimidine ( i.e. , fluorouracil , capecitabine , ftorafur without leucovorin calcium ) give concurrently sequentially Progressive disease within 2 month last dose prior chemotherapy metastatic disease OR Evidence relapse within 12 month last dose adjuvant therapy Bidimensionally measurable disease Overexpression epidermal growth factor r ( EGFr ) immunohistochemistry Must 2+ 3+ least 10 % evaluated tumor cell No know brain metastasis PATIENT CHARACTERISTICS : Age : 18 Performance status : ECOG 01 Life expectancy : Not specify Hematopoietic : Absolute neutrophil count great 1,500/mm3 Platelet count great 100,000/mm3 Hepatic : Bilirubin great 1.5 time upper limit normal ( ULN ) AST ALT great 3 time ULN Alkaline phosphatase great 3 time ULN Renal : Creatinine great 2.2 mg/dL Cardiovascular : LVEF least 45 % MUGA No myocardial infarction within past year Other : HIV negative No malignancy within past 5 year except basal cell carcinoma carcinoma situ cervix No chronic medical psychiatric condition would preclude study Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception 1 month study PRIOR CONCURRENT THERAPY : Biologic therapy : No prior EGFrtargeting agent biological agent antitumor activity Chemotherapy : See Disease Characteristics At least 30 day since prior systemic chemotherapy No 2 prior fluoropyrimidine regimen ( e.g. , fluorouracil leucovorin calcium follow capecitabine ) No prior chemotherapy , except leucovorin calcium , colorectal carcinoma Endocrine therapy : Not specify Radiotherapy : At least 30 day since prior radiotherapy Surgery : Not specify Other : At least 30 day since prior anticancer therapy No prior investigational drug potential antitumor activity No concurrent investigational drug</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2013</verification_date>
	<keyword>stage IV colon cancer</keyword>
	<keyword>stage IV rectal cancer</keyword>
	<keyword>recurrent colon cancer</keyword>
	<keyword>recurrent rectal cancer</keyword>
</DOC>